ReviewDermatology and therapy2022
Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review.
Review in Dermatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Emerging biomarkers of immune checkpoint inhibitor toxicity in triple-negative breast cancer: a mini-review.Frontiers in immunology · 2026Review
- Evaluation of skin cancer prevention properties of probiotics.Genes & nutrition · 2025Review
- Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy.Cancer immunology, immunotherapy : CII · 2025Article
- Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug.Biomedicines · 2025Review
- Dual signaling cascade regulating gut-lung axis in Interleukin-6/Interleukin-17 for NSCLC immuno pathogenesis.Frontiers in immunology · 2025Review
- Pathogenic mechanisms and etiologic aspects ofMedComm - Oncology · 2024Article
- Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti-PD-1 Therapy.Cancer immunology research · 2024Article
- Melanoma and microbiota: Current understanding and future directions.Cancer cell · 2024Review
- Understanding the relationship between breast cancer, immune checkpoint inhibitors, and gut microbiota: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2024Review
- Review
- Impact of Physical Exercise on Melanoma Hallmarks: Current Status of Preclinical and Clinical Research.Journal of Cancer · 2024Review
- Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance.Cancers · 2023Review
- Potential Pathophysiological Pathways in the Complex Relationships between OSA and Cancer.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
For patients with metastatic melanoma, immunotherapy agents represent a promising treatment option, and researchers are actively seeking to identify factors that may predict a favorable response in patients. Recent studies have elucidated possible associations between the gut microbiome and the effects of immunotherapy, where variations in the gut microbiome may influence treatment response and frequency of adverse effects. In this clinical review, we describe the current literature related to the gut microbiome in the setting of immunotherapy, and we provide an overview of interventions under investigation that may modulate the gut microbiome. These interventions include fecal microbiota transplantation, probiotics, and dietary modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.